Virologic and regimen termination surrogate end points in AIDS clinical trials

JAMA

Volumn 285, Issue 6, 2001, Pages 777-784

  Gilbert, Peter B ^a   DeGruttola, Victor ^a   Hammer, Scott M ^b   Kuritzkes, Daniel R ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; PLACEBO; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0035857355     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.6.777     Document Type: Article

References (68)

1. Surrogate endpoints in clinical trials
2. Surrogate endpoints in clinical trials
3. Evaluation of active control trials in AIDS
4. Evaluating therapeutic interventions
5. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in HIV clinical trials
6. + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine
7. + lymphocytes in patients with AIDS and AIDS-related complex
8. Surrogate markers in AIDS and cancer trials
9. CD4 cell count as a surrogate endpoint in HIV clinical trials
10. + lymphocytes as prognostic markers of HIV-1 infection
11. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study
12. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
13. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy
14. The relationship of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter
15. Circulating HIV-1 infected cell burden from seroconversion to AIDS
16. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection
17. + lymphocyte counts and the risk of progression to AIDS
18. HIV-1 RNA levels and the development of clinical disease
19. + lymphocyte count improves assessment of antiretroviral therapeutic response
20. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
21. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
22. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
23. Changing patterns of mortality across Europe in patients infected with HIV-1
24. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
25. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality
26. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
27. Deaths: Final data for 1997
28. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs
29. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors
30. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
31. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
32. HIV/AIDS patients' perspective on adhering to regimens containing protease inhibitors
33. Adherence as a particular issue with protease inhibitors
34. Single-dose pharmacokinetics of indinavir and the effect of food
35. Drug-resistance genotyping in HIV-1 therapy
36. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
37. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection
38. Randomized trial of abacavir in combination with indinavir and efavirenz in HIV-infected patients with nucleoside analog experience
39. Saquinavir in combination with ritonavir or nelfinavir together with delavirdine, adefovir, or both in HIV-infected subjects with virologic failure on indinavir: ACTG 359
40. ACTG 364-nelfinavir and/or efavirenz in combination with new NRTIs in nucleoside experienced subjects
41. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients
42. Randomized trial of abacavir (ABC) & nelfinavir (NFV) in combination with efavirenz (EFV) & adefovir dipivoxil (ADV) as salvage therapy in patients with virologic failure receiving indinavir (IDV)
43. ACTG (AIDS Clinical Trials Group) 384: A strategy trial comparing consecutive treatments for HIV-1
44. A randomized, placebo-controlled trial of saquinavir, indinavir or nelfinavir in combination with amprenavir, abacavir, efavirenz, & adefovir in patients with protease inhibitor failure
45. Reporting outcomes in Hodgkin's disease and lymphoma
46. Guidelines for reporting outcomes of lymphoma trials
47. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: The CAPS
48. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
49. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease
50. Intention to treat in clinical trials
51. Considerations in choosing a primary endpoint that measures durability of virologic suppression in an antiretroviral trial
52. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis
53. Cross-resistance analysis of human immunodeficiency virus type 1 variants selected for resistance to five different protease inhibitors
54. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to potent sulfonamide inhibitors of HIV-1 aspartyl protease
55. The safety and pharmacokinetics of 141W94: An HIV protease inhibitor
56. 141W94
57. In vitro antiviral activity of 141W94 (VX-478) in combination with other agents
58. + cells/mm 3
59. Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens
60. Adjusting for nonignorable drop-out using semiparametric nonresponse models
61. Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
62. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
63. CD4 cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
64. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease